GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.
The rate of new chronic obstructive pulmonary disease (COPD) cases decreased from 2001 to 2020, although the prevalence of ...
Friday's positive trial results for tozorakimab mark a significant inflexion point for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), ...
March 27 (Reuters) - AstraZeneca said on Friday its experimental respiratory treatment tozorakimab showed a meaningful ...
Use of CT is proven to save lives in patients eligible for lung cancer screening, which includes most patients with COPD, said Barr, professor of medicine and epidemiology at Columbia University ...
Whatever the reasons, AstraZeneca has emerged as the first IL-33 player to show consistent efficacy. Sanofi and Regeneron ...
Everyday Health on MSN
The best breathing exercises for COPD
Breathing exercises can help improve your quality of life when you have COPD. Here are four exercises to strengthen your lungs and help you breathe easier.
Tozorakimab is an investigational monoclonal antibody designed to bind and inhibit interleukin-33, an alarmin cytokine.
Chronic obstructive pulmonary disease, or COPD, is the 5th-leading cause of death in the United States and the cause of more ...
You did it to yourself.” This is one of the things that patients who are diagnosed with COPD often hear because of the stigma ...
Top-line results from the OBERON and TITANIA trials showed that tozorakimab reduced the annualised rate of moderate-to-severe ...
By Pushkala Aripaka, Nithyashree R B and Maggie Fick March 27 (Reuters) - AstraZeneca's experimental drug tozorakimab reduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results